Related Experiment Video
Updated: Aug 18, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
A novel self-assembled targeted nanoparticle platform based on carboxymethylcellulose co-delivery of anticancer drugs
Lin Dai1, Ke-Feng Liu, Chuan-Ling Si
1Beijing Key Laboratory of Lignocellulosic Chemistry, Beijing Forestry University, Beijing 100083, P. R. China. ljd2012@bjfu.edu.cn.
Abstract:
Single-drug therapy for cancer is greatly hampered by its non-specific delivery to the target tissue, limited efficacies, poor tolerability, and resistance profiles. In order to overcome these limitations, we developed a new targeted nanoparticle platform for co-delivery of two different anticancer drugs. A conjugate based on carboxymethylcellulose (CMC) was first synthesized by introducing hydrophilic molecules (PEG), target molecules (folate), and drug molecules (betulinic acid) into CMC. Then another anticancer drug hydroxycamptothecine (HCPT) was encapsulated into the nanoparticles from the conjugate using a simple nanoprecipitation method. The obtained nanoparticles possessed appropriate size (∼180 nm), high drug loading efficiency (∼23 wt% BA, 21.15 wt% HCPT), a slow drug release rate, higher blood circulation half-time of free BA (6.4-fold) and HCPT (6.0-fold), and high synergetic activity of BA and HCPT toward cancer cells. Furthermore, the targeted nanoparticles showed rapid cellular uptake by tumor cells. The antitumor effect of the nanoparticles in a mouse tumor xenograft model exhibited a much better tumor inhibition efficacy and fewer side effects than that of BA and HCPT, strongly supporting their application as efficient carriers for anticancer therapy.
Insights
This study introduces a novel targeted nanoparticle platform for co-delivering two anticancer drugs, improving efficacy and reducing side effects for cancer therapy. The new system demonstrates enhanced drug delivery and significant tumor inhibition in preclinical models.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Oncology
Background:
- Single-drug cancer therapy faces challenges like non-specific delivery, low efficacy, and drug resistance.
- Targeted drug delivery systems are crucial for overcoming these limitations in cancer treatment.
Purpose of the Study:
- To develop a targeted nanoparticle platform for the co-delivery of two distinct anticancer drugs.
- To enhance drug efficacy and reduce side effects through improved delivery and synergistic action.
Main Methods:
- Synthesis of a carboxymethylcellulose (CMC)-based conjugate incorporating polyethylene glycol (PEG), folate, and betulinic acid (BA).
- Encapsulation of hydroxycamptothecine (HCPT) into CMC-based nanoparticles via nanoprecipitation.
- Characterization of nanoparticle size, drug loading efficiency, release kinetics, and in vivo antitumor activity in a mouse xenograft model.
Main Results:
- Developed nanoparticles with optimal size (~180 nm) and high drug loading efficiency (23 wt% BA, 21.15 wt% HCPT).
- Demonstrated sustained drug release, prolonged blood circulation half-time for both drugs (6.4-fold for BA, 6.0-fold for HCPT), and significant synergistic anticancer activity.
- Observed rapid cellular uptake by tumor cells and superior tumor inhibition with reduced side effects in vivo compared to individual drug treatments.
Conclusions:
- The developed targeted nanoparticle platform effectively co-delivers two anticancer drugs, showing enhanced therapeutic efficacy and improved pharmacokinetic profiles.
- This novel nanocarrier system holds significant promise for improving cancer therapy by leveraging synergistic drug action and targeted delivery.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers